Breaking News

TriLink BioTechnologies Expands mRNA Manufacturing Facility

GMP facility expected to simplify the mRNA drug substance development process.

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, is expanding its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials. The new facility is scheduled to open in early 2024. TriLink has reliably delivered GMP se...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters